PURPOSE: Relapse of tumours in patients with oral cavity squamous cell carcinoma (OSCC) is associated with a dismal outcome. In this prospective study, we sought to investigate the clinical significance of the preoperative maximal standardized uptake value (SUVmax) at the neck lymph nodes in selecting patients with OSCC for salvage therapy after relapse. METHODS: Between 2002 and 2007, 108 patients with early relapse of OSCC (n=75) or late relapse of OSCC (n=33) were identified. Salvage therapy was performed in 47 patients. All patients underwent 2-deoxy-2[(18)F]-fluoro-D: -glucose positron emission tomography during the 2 weeks before surgery and neck dissection. All patients were followed for 12 months or more after surgery or until death. The optimal cut-off value for the neck lymph node SUVmax (SUVnodal-max) was selected according to the 5-year disease-specific survival (DSS) rate. Independent risk factors were identified by Cox regression analysis. RESULTS: The mean follow-up for all patients was 20.3 months (41.1 months for surviving patients). In the early relapse group, several prognostic factors were identified in univariate and multivariate analyses, including a SUVnodal-max value of >or=4.2. A scoring system based on univariate analysis was formulated. Patients with a score of 0 had a better 5-year DSS than those with scores of 1 or higher (58% vs. 5%, p=0.0003). In patients with late relapse, a SUVnodal-max value of >or=4.2 had the highest prognostic value for predicting the 5-year DSS (45% vs. 0%, p=0.0005). CONCLUSION: Among patients with relapsed OSCC, the SUVnodal-max value may aid in selecting patients for salvage therapy.
PURPOSE: Relapse of tumours in patients with oral cavity squamous cell carcinoma (OSCC) is associated with a dismal outcome. In this prospective study, we sought to investigate the clinical significance of the preoperative maximal standardized uptake value (SUVmax) at the neck lymph nodes in selecting patients with OSCC for salvage therapy after relapse. METHODS: Between 2002 and 2007, 108 patients with early relapse of OSCC (n=75) or late relapse of OSCC (n=33) were identified. Salvage therapy was performed in 47 patients. All patients underwent 2-deoxy-2[(18)F]-fluoro-D: -glucose positron emission tomography during the 2 weeks before surgery and neck dissection. All patients were followed for 12 months or more after surgery or until death. The optimal cut-off value for the neck lymph node SUVmax (SUVnodal-max) was selected according to the 5-year disease-specific survival (DSS) rate. Independent risk factors were identified by Cox regression analysis. RESULTS: The mean follow-up for all patients was 20.3 months (41.1 months for surviving patients). In the early relapse group, several prognostic factors were identified in univariate and multivariate analyses, including a SUVnodal-max value of >or=4.2. A scoring system based on univariate analysis was formulated. Patients with a score of 0 had a better 5-year DSS than those with scores of 1 or higher (58% vs. 5%, p=0.0003). In patients with late relapse, a SUVnodal-max value of >or=4.2 had the highest prognostic value for predicting the 5-year DSS (45% vs. 0%, p=0.0005). CONCLUSION: Among patients with relapsed OSCC, the SUVnodal-max value may aid in selecting patients for salvage therapy.
Authors: Heiko Schöder; Diane L Carlson; Dennis H Kraus; Hilda E Stambuk; Mithat Gönen; Yusuf E Erdi; Henry W D Yeung; Andrew G Huvos; Jatin P Shah; Steven M Larson; Richard J Wong Journal: J Nucl Med Date: 2006-05 Impact factor: 10.057
Authors: R J Wong; D T Lin; H Schöder; S G Patel; M Gonen; S Wolden; D G Pfister; J P Shah; S M Larson; D H Kraus Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: Martin Kunkel; Gregor J Förster; Torsten E Reichert; Jong-Hyeon Jeong; Peter Benz; Peter Bartenstein; Wilfried Wagner; Theresa L Whiteside Journal: Cancer Date: 2003-11-15 Impact factor: 6.860
Authors: Sulsal Haque; Vidhya Karivedu; Muhammed K Riaz; David Choi; Logan Roof; Sarah Z Hassan; Zheng Zhu; Roman Jandarov; Vinita Takiar; Alice Tang; Trisha Wise-Draper Journal: Oral Oncol Date: 2018-11-16 Impact factor: 5.337
Authors: Lisa W Lekanne Dit Deprez; Grégoire B Morand; Christian Thüring; Shila Pazahr; Martin W Hüllner; Martina A Broglie Journal: Eur Arch Otorhinolaryngol Date: 2021-11-15 Impact factor: 2.503
Authors: Bong-Il Song; Hae Won Kim; Kyoung Sook Won; Seung Wan Ryu; Soo Sang Sohn; Yu Na Kang Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889